Major pharmaceutical companies are eager to partner with or acquire ADC developers to enhance their oncology pipelines. ADCs combine a cytotoxic payload, a monoclonal antibody (mAb), and a chemical linker, offering greater target specificity and a wider therapeutic index than traditional therapies, delivering toxic agents directly to cancer cells while sparing healthy tissues. specific antigens in ovarian, lung, and other solid tumors, aiming to provide safer and more effective treatment options. Clarivate ...